Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug shrink Hard-to-Treat eye cancer?

NCT ID NCT05415072

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests an experimental drug called DYP688 in people with metastatic uveal melanoma, a rare eye cancer that has spread, and other melanomas with specific genetic mutations. The study aims to find a safe dose and see whether the drug can shrink tumors. Participants receive DYP688 alone, and researchers monitor side effects and anti-cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called DYP688
What this could lead to
If it works, this could point toward a new treatment option for a rare and aggressive eye cancer that currently has few effective therapies.
What could go wrong
This is an early-phase trial, so the drug may not prove safe or effective. Side effects could be significant, and the small number of participants limits what can be concluded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CUTANEOUS MELANOMA WITH GNAQ/11 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma mucosal melanoma neoplasm ocular cancer uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC UVEAL MELANOMA

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloane Ketterin Cancer Ctr

    New York, New York, 10065, United States

  • Novartis Investigative Site

    Westmead, New South Wales, 2145, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    Paris, 75231, France

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Leiden, South Holland, 2333 ZA, Netherlands

  • Novartis Investigative Site

    Madrid, 28050, Spain

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.